1037 related articles for article (PubMed ID: 9181234)
1. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
[TBL] [Abstract][Full Text] [Related]
2. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
3. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes.
Arca MJ; Krauss JC; Strome SE; Cameron MJ; Chang AE
Cancer Immunol Immunother; 1996 May; 42(4):237-45. PubMed ID: 8665571
[TBL] [Abstract][Full Text] [Related]
4. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
Parviz M; Chin CS; Graham LJ; Miller C; Lee C; George K; Bear HD
Cancer Immunol Immunother; 2003 Dec; 52(12):739-50. PubMed ID: 12827306
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
6. gamma-Interferon plays a key role in T-cell-induced tumor regression.
Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
Fleming MD; Bear HD; Lipshy K; Kostuchenko PJ; Portocarero D; McFadden AW; Barrett SK
J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):147-55. PubMed ID: 8770770
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
10. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
11. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
Shiloni E; Karp SE; Custer MC; Shilyansky J; Restifo NP; Rosenberg SA; Mulé JJ
Cancer Immunol Immunother; 1993 Oct; 37(5):286-92. PubMed ID: 8402732
[TBL] [Abstract][Full Text] [Related]
12. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.
Miguel A; Herrero MJ; Sendra L; Botella R; Algás R; Sánchez M; Aliño SF
Cancer Gene Ther; 2013 Oct; 20(10):576-81. PubMed ID: 23969885
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
14. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.
Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590
[TBL] [Abstract][Full Text] [Related]
15. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases.
Tuttle TM; Inge TH; Lind DS; Bear HD
Surg Oncol; 1992 Aug; 1(4):299-307. PubMed ID: 1341264
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
18. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
[TBL] [Abstract][Full Text] [Related]
19. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
20. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]